Quarterly ResultMay 14, 2026, 04:52 PM
Atrium Therapeutics Q1 Collaboration Revenue $19.6M; Net Loss $(16.6)M
AI Summary
Atrium Therapeutics, Inc. reported its first quarter 2026 financial results, including collaboration revenue of $19.6 million and a net loss of $(16.6) million. The company highlighted its recent launch as an independent public entity and the achievement of a $15 million milestone payment from Bristol Myers Squibb. Atrium Therapeutics also progressed its lead development program, ATR 1072, towards clinical trials and ended the quarter with a strong cash position of $267.8 million.
Key Highlights
- Launched as an independent, publicly traded precision cardiology company on February 27, 2026.
- Earned a $15 million milestone payment from Bristol Myers Squibb for a development candidate.
- Collaboration revenue for Q1 2026 was $19.6 million, primarily from the BMS milestone.
- Research and development expenses were $16.7 million for Q1 2026.
- General and administrative expenses were $20.3 million for Q1 2026.
- Reported a net loss of $(16.6) million for the first quarter of 2026.
- Cash and cash equivalents stood at $267.8 million as of March 31, 2026.
- Anticipates submitting an IND application for ATR 1072 in the second half of 2026.